<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管高解释</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;ff=20250215151018&amp;fc = 20230708114047<description>心血管高额外版：PubMed的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;ff=20250215151018&amp;fc=20230708114047" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS提要（2.18.0.post9+E462414）</generator><language> en</language><lastbuilddate>星期六，2025年2月15日20:10:18 +0000</lastbuilddate><pubDate> Fri, 14 Feb 2025 06:00:00 -0500</pubDate><ttl> 120</ttl><item><title>果蝇中的男性互动形状伴侣选择</title><link/>https://pubmed.ncbi.nlm.nih.gov/39952248/？ 708114047＆ff = 20250215151018＆v = 2.18.0.post9+e462414<description>许多物种的雄性都将行为特征进化为吸引女性和驱除风险。 - 在指导生殖策略的协同协作中，我们发现男性通过与一位具有侵略性的翅膀的女性求爱来抵御竞争的求婚者，这既是击退竞争者又产生竞争者... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> 。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">许多物种的雄性都将行为特征进化为吸引女性和驱除风险。 - 在指导生殖策略的协同工作中，我们发现男性通过与攻击性的翅膀轻弹的求爱来抵御竞争求婚者。两个高阶电路节点-P1A和PC1X神经元 - 招募了男性，可以灵活地将这些激动的动作与求爱的展示交织在一起，从而持续地追求女性，直到他们的丝带falsettos。通过男性互动，强调了男性颠覆自己的风险的能力，这对于他的复制成功至关重要。</p><p style="color: lightgray"> PMID <a href=https://doi.org/10.1016/j.cell.2025.01.008>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39952248/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250215151018&v=2.18.0.post9+e462414">39952248</a> |</p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39952248</guid><pubDate> Fri, 14 Feb 2025 06:00:00 -0500</pubDate><dc:creator>汤姆·欣德马什·斯滕（Tom Hindmarsh Sten）</dc:creator><dc:creator> Rufei li</dc:creator><dc:creator>弗洛里安·荷兰德（Florian Hollunder）</dc:creator><dc:creator>阴影Eleazer</dc:creator><dc:creator>凡妮莎·鲁塔（Vanessa Ruta）</dc:creator><dc:date> 2025-02-14</dc:date><dc:source>细胞</dc:source><dc:title>果蝇中的男性互动形状伴侣选择</dc:title><dc:identifier>PMID：39952248</dc:identifier><dc:identifier> doi：10.1016/j.cell.2025.01.008</dc:identifier></item><item><title>同义突变通过破坏M6a依赖性mRNA代谢来促进肿瘤发生</title><link/>https://pubmed.ncbi.nlm.nih.gov/39952247/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250215151018&amp;v=2.18.0.post9+e462414<description>癌细胞在肿瘤发生过程中获取许多突变，包括不改变蛋白质的氨基酸序列的同义突变。具有扰动M⁶A修饰模式的潜力的癌症基因组，我们称之为“M⁶A中断突变（M⁶A-DMS）”。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> 。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">癌细胞在肿瘤发生过程中获取许多突变，包括不改变蛋白质的氨基酸序列<sup>的</sup>同义突变。癌症基因<sup>组</sup>的突变具有<sup>扰动</sup>M <sup>6</sup>的一种修饰模式，我们称之为“ M <sup>6</sup> A A DISPRIENS突变（M <sup>6</sup> A-DMS）”。 DMS）或错义M <sup>6</sup> A-DMS <sup>（</sup> MM <sup>6</sup> <sup>A</sup> -DMS）突变，前者富含肿瘤抑制基因，例如CDKN2A和BRCA2 A-DM位点还会影响mRNA稳定性，将CDKN2A SM <sup>6</sup> A-DMS引入癌细胞，而BRCA2 SM <sup>6</sup> A-DMS敏感的肿瘤对聚（ADP-核糖）聚合酶抑制剂（PARPI） SM <sup>6</sup> A-DM作为潜在的致癌驱动因素，揭示了对肿瘤发生及其他地区的同义突变的影响。</p><p style="color: lightgray"> PMID <a href=https://doi.org/10.1016/j.cell.2025.01.026>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39952247/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250215151018&v=2.18.0.post9+e462414">39952247</a> |</p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39952247</guid><pubDate> Fri, 14 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Yiheng Lan</dc:creator><dc:creator> Zhen Xia</dc:creator><dc:creator> Qizhe Shao</dc:creator><dc:creator>彭林</dc:creator><dc:creator>金正恩·卢（Jinhong Lu）</dc:creator><dc:creator>小人</dc:creator><dc:creator>郑郑</dc:creator><dc:creator>Di Chen</dc:creator><dc:creator> Yanmei Dou</dc:creator><dc:creator> Qi Xie</dc:creator><dc:date> 2025-02-14</dc:date><dc:source>细胞</dc:source><dc:title>同义突变通过破坏M6a依赖性mRNA代谢来促进肿瘤发生</dc:title><dc:identifier>PMID：39952247</dc:identifier><dc:identifier> doi：10.1016/j.cell.2025.01.026</dc:identifier></item><item><title>基于进化史的Coq &lt;ub>; 10 &lt;sub>; 10</title><link/> https://pubmed.ncbi.nlm.nih.gov/39952246/？ 708114047＆ff = 20250215151018＆v = 2.18.0.post9+e462414<description>辅酶Q（COQ）对于通过线粒体呼吸产生能量至关重要，它是一种补充剂，通常用于促进心血管健康，但谷物和一些蔬菜/水果作物合成COQ（9）九个在农作物中的链链链（10）产量会受益于人类健康，但这是因为基于广泛的研究而造成的。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> 。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">辅酶Q（COQ）对于通过线粒体呼吸产生能量至关重要，<sub>它</sub>是一种最常用于促进心血管健康的<sub>补充剂</sub>单位在农作物中产生了COQ <sub>10的</sub>生产，这将使人类健康受益，但这是因为对控制链长度的特定残差是基于对Coq <sub>9</sub>和Coq <sub>9</sub>的广泛研究土地植物和相关的coq1序列变化，我们鉴定了在多个被子植物谱系中独立发生的coq1催化口袋的钥匙氨基酸变化，并反复驱动COQ <sub>9的</sub>形成，我们使用基因编辑来修改天然的天然。大米和小麦的COQ1基因生产COQ <sub>10</sub> ，为开发COQ <sub>10</sub>的其他饮食来源铺平了道路。</p><p style="color: lightgray"> PMID <a href=https://doi.org/10.1016/j.cell.2025.01.023>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39952246/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250215151018&v=2.18.0.post9+e462414">39952246</a> |</p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39952246</guid><pubDate> Fri, 14 Feb 2025 06:00:00 -0500</pubDate><dc:creator> jing-jing xu</dc:creator><dc:creator> Yuan Lei</dc:creator><dc:creator>张张</dc:creator><dc:creator>Jian-Xu li</dc:creator><dc:creator> Qiupeng Lin</dc:creator><dc:creator> Xiang-Dong Wu</dc:creator><dc:creator> Yu-guo江</dc:creator><dc:creator>Wenyi Zhang</dc:creator><dc:creator> Runtong Qian</dc:creator><dc:creator> Shu-Yi Xiong</dc:creator><dc:creator> kuo tan</dc:creator><dc:creator> Yu Jia</dc:creator><dc:creator> Qiang Zhou</dc:creator><dc:creator> YAN江</dc:creator><dc:creator>挂风扇</dc:creator><dc:creator>Yan-Bo Huang</dc:creator><dc:creator> Ling-Jian Wang</dc:creator><dc:creator> Ji-Yun Liu</dc:creator><dc:creator> Yu Kong</dc:creator><dc:creator> Zhao</dc:creator><dc:creator>梁阳</dc:creator><dc:creator>Jinxing Liu</dc:creator><dc:creator> Yong-Hong Hu</dc:creator><dc:creator> Shuai Zhan</dc:creator><dc:creator> Caixia Gao</dc:creator><dc:creator>小杨陈</dc:creator><dc:date>2025-02-14</dc:date><dc:source>细胞</dc:source><dc:title>基于进化史的Coq &lt;ub>; 10 &lt;sub>; 10</dc:title><dc:identifier> PMID：39952246</dc:identifier><dc:identifier> doi：10.1016/j.cell.2025.01.023</dc:identifier></item><item><title>主动脉瓣修复手术的现状</title><link/>https://pubmed.ncbi.nlm.nih.gov/39950993/？ 08114047＆ff = 20250215151018＆v = 2.18.0.post9+e462414<description>严重的主动脉瓣反流（如果未及时治疗）可以显着影响患者的生存率，即三尖瓣主动脉瓣和双刺区主动脉瓣患者的生存率，后者对根部解剖学的了解及其生理学大大增加。主动脉瓣修复手术。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 2月14日：EHAF038。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">严重的主动脉瓣反流（如果未及时治疗）可以显着影响患者的生存率，即三尖瓣主动脉瓣和双刺区主动脉瓣患者的生存率，后者对根部解剖学的了解及其生理学大大增加。主动脉瓣修复手术修复双尖瓣可能会根据不同的瓣膜表型而变化。患者应旨在避免主动脉瓣置换及其相关并发症。</p><p style="color: lightgray"> PMID <a href=https://doi.org/10.1093/eurheartj/ehaf038>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39950993/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250215151018&v=2.18.0.post9+e462414">39950993</a> |</p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39950993</guid><pubDate> Fri, 14 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Ruggero de Paulis</dc:creator><dc:creator> Ilaria Chirichilli</dc:creator><dc:creator>劳伦特·德·科霍夫（Laurent de Kerchove）</dc:creator><dc:creator>亚历山德罗·德拉·科尔特（Alessandro Della Corte）</dc:creator><dc:creator> Gebrine El Khoury</dc:creator><dc:creator> Hector I Michelena</dc:creator><dc:creator> Andrea Salica</dc:creator><dc:creator> Hans-Joachimschäfers</dc:creator><dc:date> 2025-02-14</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>主动脉瓣修复手术的现状</dc:title><dc:identifier>PMID：39950993</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf038</dc:identifier></item><item><title>在临床试验中扩大甘油三酸酯范围：治疗机会</title><link/>https://pubmed.ncbi.nlm.nih.gov/39950981/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250215151018&amp;v=2.18.0.post9+e462414<description>结论：患有轻度至中度高甘油三酸酯血症的个体可能不会表达与整个血浆甘油三酸酯范围内观察到的相同的心血管风险。不是先前的胰腺炎病史，也没有过多的酒精摄入量。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 2月14日：EHAF074：10.1093/EurheartJ/EHAF074。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：指南重点介绍了2.3至5.6 mmol/L（200和499 mg/dl）的个体。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：根据基线甘油三酸酯的基线甘油三酸酯的基线甘油三酸酯在全部生物学范围内，从哥本哈根一般人群研究中，有277777777777777777777777777777777777777777777777777777777777777777777777777777777757个基线甘油三酸酯介于2.3和5.6 mmol/5.6 mmol/ll甘油酸的个体中哥本哈根一般人口研究和妇女健康研究队列中，在31272名受到突出，减少IT和力量试验的轻度至中度高甘油三酸酯血症中的患者中。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在整个范围内增加甘油三酸酯（0.3至11.2 mmol/L）与大型心血管事件的风险增加有关（n = 12 241），危险比率（95％）。 /l）]从最低至最高甘油三酸酯四分位数的主要心血管事件（n = 3928）为1.0 [参考率（范围：&lt;2.5）]，0.95 [0.87-1.04（范围：2.5至3.0）]，1.04 [0.95-- [0.95--- 1.13（范围：3.0至&lt;3.6）和1.13 [1.04-1.23（范围：≥3.6）]。参考（突出/减少/强度的范围：&lt;2.6/2.0/2.2）]，1.01 [0.93-1.10（范围：2.6至&lt;3.1/2.0至&lt;3.1/2.0至&lt;2.5/2.2至&lt;2.7）]，1.05 [0.96-- 1.14（范围：3.1至&lt;3.9/2.5至&lt;3.1/2.7至&lt;3.5）]和1.09 [1.00-1.19（范围：≥3.9/3.1/3.5）。有心血管或全因死亡的风险。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：患有轻度至中度高甘油三酸酯血症的个体可能不会表达与整个血浆甘油三酸酯范围内观察到的相同的心血管风险。不是先前的胰腺炎病史，也没有过多的酒精摄入量。</p><p style="color: lightgray"> PMID <a href=https://doi.org/10.1093/eurheartj/ehaf074>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39950981/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250215151018&v=2.18.0.post9+e462414">39950981</a> |</p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39950981</guid><pubDate> Fri, 14 Feb 2025 06:00:00 -0500</pubDate><dc:creator>询问Nordestgaard</dc:creator><dc:creator> Aruna d Pradhan</dc:creator><dc:creator>布伦丹·M·埃弗里特（Brendan M Everett）</dc:creator><dc:creator> Jean G MacFadyen</dc:creator><dc:creator> Deepak L Bhatt</dc:creator><dc:creator>弗兰克·LJ Visseren</dc:creator><dc:creator>彼得·利比</dc:creator><dc:creator>Raul D Santos</dc:creator><dc:creator>史蒂文·尼森（Steven E Nissen）</dc:creator><dc:creator> BørgeGNordestgaard</dc:creator><dc:creator>保罗·麦德克（Paul M Ridker）</dc:creator><dc:date> 2025-02-14</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>在临床试验中扩大甘油三酸酯范围：治疗机会</dc:title><dc:identifier>PMID：39950981</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf074</dc:identifier></item><item><title>每周期刊扫描：经导管与联合严重主动脉瓣狭窄和阻塞性冠状动脉疾病的手术治疗</title><link/>https://pubmed.ncbi.nlm.nih.gov/39950980/？ 08114047＆ff = 20250215151018＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 2月14日：EHAF023：10.1093/Eurheartj/ehaf023。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID <a href=https://doi.org/10.1093/eurheartj/ehaf023>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39950980/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250215151018&v=2.18.0.post9+e462414">39950980</a> |</p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39950980</guid><pubDate> Fri, 14 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Rocco Vergallo</dc:creator><dc:creator> Daniela Pedicino</dc:creator><dc:date> 2025-02-14</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>每周期刊扫描：经导管与联合严重主动脉瓣狭窄和阻塞性冠状动脉疾病的手术治疗</dc:title><dc:identifier>PMID：39950980</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf023</dc:identifier></item><item><title>载脂蛋白A-1淀粉样蛋白在主动脉夹层中的潜在作用</title><link/>https://pubmed.ncbi.nlm.nih.gov/39950978/？ 08114047＆ff = 20250215151018＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 2月14日：EHAF096。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID <a href=https://doi.org/10.1093/eurheartj/ehaf096>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39950978/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250215151018&v=2.18.0.post9+e462414">39950978</a> |</p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39950978</guid><pubDate> Fri, 14 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Hiroyuki Otsuka</dc:creator><dc:creator> Nobuhiro Tahara</dc:creator><dc:creator> Eiki Tayama</dc:creator><dc:date> 2025-02-14</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>载脂蛋白A-1淀粉样蛋白在主动脉夹层中的潜在作用</dc:title><dc:identifier>PMID：39950978</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf096</dc:identifier></item><item><title>我们如何咨询外周心肌病后希望随后怀孕的患者？</title><link/> https://pubmed.ncbi.nlm.nih.gov/39950969/？ 08114047＆ff = 20250215151018＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025年2月14日：Ehae888：10.1093/Eurheartj/ehae888。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID <a href=https://doi.org/10.1093/eurheartj/ehae888>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39950969/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250215151018&v=2.18.0.post9+e462414">39950969</a> |</p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39950969</guid><pubDate> Fri, 14 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Olayinka Agboola</dc:creator><dc:creator> Garima Sharma</dc:creator><dc:date> 2025-02-14</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>我们如何咨询外周心肌病后希望随后怀孕的患者？</dc:title><dc:identifier> PMID：39950969</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehae888</dc:identifier></item><item><title>心肌细胞PRL2通过直接去磷酸化AMPKα2促进心脏肥大</title><link/>https://pubmed.ncbi.nlm.nih.gov/39950300/？ 8114047＆ff = 20250215151018＆v = 2.18.0.post9+e462414<description>结论：这项研究表明，作为一种新型AMPK调节磷酸酶，PRL2促进了心肌细胞中的线粒体不稳定性和肥大性损伤，并为PLR2提供了治疗心力衰竭的未来药物发育的潜在靶标。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：病理心脏肥大会导致心力衰竭。心脏肥大。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：PRL2敲除小鼠进行血管紧张素II输注或横向主动脉收缩以诱导心肌肥大和心脏功能障碍。 AMP激活的蛋白激酶α2）作为AMPKα2的突变质粒的相互作用蛋白。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在小鼠和心力衰竭的患者中，PRL2在肥厚的心肌组织中观察到了明显的上调。敲除或静音维持AMPK <sup>T172</sup>磷酸化和随后的线粒体完整性在血管紧张素II-II挑战的心脏组织或心肌细胞中，基于质谱的相互作用组表明AMPKα2亚基是AMPKα2亚基作为PRL2的底物。通过其活性位点C46进行DEPHOPHORPARTATEAMPKα2T172。与腺相关的病毒9介导<sup>的</sup>心肌细胞<sup>PRL2</sup>缺乏也保护心脏线粒体功能，并在血管素蛋白II挑战小鼠中显示出心脏保护作用</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这项研究表明，作为一种新型AMPK调节磷酸酶，PRL2促进了心肌细胞中的线粒体不稳定性和肥大性损伤，并为PLR2提供了治疗心力衰竭的未来药物发育的潜在靶标。</p><p style="color: lightgray"> PMID <a href=https://doi.org/10.1161/CIRCRESAHA.124.325262>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39950300/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250215151018&v=2.18.0.post9+e462414">39950300</a> |</p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39950300</guid><pubDate> Fri, 14 Feb 2025 06:00:00 -0500</pubDate><dc:creator> XUE HAN</dc:creator><dc:creator> Qiaojuan Shi</dc:creator><dc:creator> yu tu</dc:creator><dc:creator> Jiajia Zhang</dc:creator><dc:creator>孟阳王</dc:creator><dc:creator>weiqi li</dc:creator><dc:creator> Yanan Liu</dc:creator><dc:creator> Ruyi Zheng</dc:creator><dc:creator> Jiajia Wei</dc:creator><dc:creator> shiju ye</dc:creator><dc:creator> Yanmei Zhang</dc:creator><dc:creator> bozhi ye</dc:creator><dc:creator> Yi Wang</dc:creator><dc:creator> Huazhong Ying</dc:creator><dc:creator>古梁</dc:creator><dc:date>2025-02-14</dc:date><dc:source>循环研究</dc:source><dc:title>心肌细胞PRL2通过直接去磷酸化AMPKα2促进心脏肥大</dc:title><dc:identifier>PMID：39950300</dc:identifier><dc:identifier> doi：10.1161/circresaha.124.325262</dc:identifier></item><item><title>专注于主动脉狭窄预防和二尖瓣反流诊断</title><link/>https://pubmed.ncbi.nlm.nih.gov/39947236/？ 708114047＆ff = 20250215151018＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> EUR HEART J. 2025 2月14日； 46（7）：595-597：10.1093/eurheartj/ehaf015。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID <a href=https://doi.org/10.1093/eurheartj/ehaf015>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39947236/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250215151018&v=2.18.0.post9+e462414">39947236</a> |</p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39947236</guid><pubDate> Thu, 13 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Filippo Crea</dc:creator><dc:date> 2025-02-13</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>专注于主动脉狭窄预防和二尖瓣反流诊断</dc:title><dc:identifier>PMID：39947236</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf015</dc:identifier></item><item><title>通过减少斯特龙酮的渗出剂对Striga寄生虫的抗性</title><link/>https://pubmed.ncbi.nlm.nih.gov/39947180/？ 708114047＆ff = 20250215151018＆v = 2.18.0.post9+e462414<description> Striga位置的寄生虫对全球粮食生产构成了重大威胁，用PI缺乏或SL GR24^（5DS）处理的高粱的转录组和功能分析识别SL的两个ABC转运蛋白G（ABCG）转运蛋白，高粱Biolocolor strigolactones transporters Transporter 1（SBSLT1）和... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> 。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Striga位置的寄生虫对全球粮食生产构成了重大威胁，用PI缺乏或SL GR24 <sup>5DS</sup>处理的高粱的转录组和功能分析确定了SL，高粱Biocolor Strigolactones Transporter 1（SBSLT1）（SBSLT1）的两个ABC转运蛋白G（ABCG）转运蛋白。 SL转运通道中的保守氨基酸对于这些转运蛋白的单敲门或双重敲除的sl传输通道显着降低了SL的分泌，从而导致田间实验中的Striga发芽和寄生虫下降，并在Striga Infestation下降低晶粒损失。因此，这项研究描述了单子叶植物中SL渗出的机制，并定义了SL转运蛋白功能必不可少的一致性，从而提供了增强作物对纹状体寄生虫抗性的潜在策略。</p><p style="color: lightgray"> PMID <a href=https://doi.org/10.1016/j.cell.2025.01.022>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39947180/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250215151018&v=2.18.0.post9+e462414">39947180</a> |</p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39947180</guid><pubDate> Thu, 13 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Jiayang Shi</dc:creator><dc:creator> Cuo Mei</dc:creator><dc:creator> Fengyong GE</dc:creator><dc:creator>青金胡</dc:creator><dc:creator>xinwei禁令</dc:creator><dc:creator>跑夏</dc:creator><dc:creator>Peiyong Xin</dc:creator><dc:creator> Shujing Cheng</dc:creator><dc:creator>张张</dc:creator><dc:creator>jiawei nie</dc:creator><dc:creator> Shiqi Zhang</dc:creator><dc:creator>小田马</dc:creator><dc:creator>Yi Wang</dc:creator><dc:creator> Jinfang Chu</dc:creator><dc:creator> Yuhang Chen</dc:creator><dc:creator> Bing Wang</dc:creator><dc:creator> Weihua Wu</dc:creator><dc:creator>贾阳李</dc:creator><dc:creator>Qi Xie</dc:creator><dc:creator> feifei yu</dc:creator><dc:date> 2025-02-13</dc:date><dc:source>细胞</dc:source><dc:title>通过减少斯特龙酮的渗出剂对Striga寄生虫的抗性</dc:title><dc:identifier>PMID：39947180</dc:identifier><dc:identifier> doi：10.1016/j.cell.2025.01.022</dc:identifier></item><item><title> ARFGAP2促进刺激质子通道活性，细胞因子过境和自身炎症</title><link/>https://pubmed.ncbi.nlm.nih.gov/39947179/？ 708114047＆ff = 20250215151018＆v = 2.18.0.post9+e462414<description>干扰素基因（STING）的刺激剂在胞质DNA传感器循环鸟苷单磷酸 -  AMP合酶（CGAS）下游传播，导致细胞因子的转录上调，但是，IRF3和IFNAR1等刺激性信号途径的成分。对于刺激功能获得的自身炎性疾病（与婴儿期[SAVI]的发作相关的血管病[SAVI]）的小鼠表明，Sting也是质子通道的作用。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> 。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">干扰素基因（STING）的刺激剂在胞质DNA传感器循环鸟苷单磷酸 -  AMP合酶（CGAS）下游传播，导致细胞因子的转录上调，但是，IRF3和IFNAR1等刺激性信号途径的成分。对于sting功能的自身炎性疾病（在婴儿期[SAVI]）小鼠中与sting相关的血管病表明，Sting还可以作为质子通道，使Golgi Applatus脱氧。成熟和运输，我们假设刺激质子通道的活性会影响多种高尔基体功能，我们表明，刺激的质子外排在非转录中调节蛋白质cargos的高尔基体运输。 STING介导的质子外排和信号传导的特定双重调节剂。造血细胞中的细胞因子释放，显着导致自炎性疾病发病机理。</p><p style="color: lightgray"> PMID <a href=https://doi.org/10.1016/j.cell.2025.01.027>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39947179/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250215151018&v=2.18.0.post9+e462414">39947179</a> |</p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39947179</guid><pubDate> Thu, 13 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Subhajit Poddar</dc:creator><dc:creator>塞缪尔·沙文（Samuel D Chauvin）</dc:creator><dc:creator>克里斯托弗·H·阿切尔（Christopher H Archer）</dc:creator><dc:creator>魏袋</dc:creator><dc:creator>Jean A Castillo-Badillo</dc:creator><dc:creator> XIN YIN</dc:creator><dc:creator> W MIGUEL DISBENNETT</dc:creator><dc:creator> Cathrine是矿工</dc:creator><dc:creator>乔·霍利（Joe A Holley）</dc:creator><dc:creator> Teresa V Naismith</dc:creator><dc:creator> W亚历山大·斯坦森</dc:creator><dc:creator>xiioochao wei</dc:creator><dc:creator> yue ning</dc:creator><dc:creator> Jiayuan fu</dc:creator><dc:creator> Trini A Ochoa</dc:creator><dc:creator>尼哈利调查</dc:creator><dc:creator>Shivam a zaver</dc:creator><dc:creator>金伯利的wodzanowski</dc:creator><dc:creator>凯瑟琳·巴尔卡（Katherine R Balka）</dc:creator><dc:creator> Rajan Venkatraman</dc:creator><dc:creator> canyu刘</dc:creator><dc:creator>凯利·罗马</dc:creator><dc:creator>威尔·贝利斯</dc:creator><dc:creator>Yoko Shiba</dc:creator><dc:creator>萨拉樱桃</dc:creator><dc:creator>阳光明媚</dc:creator><dc:creator>Clay F Semenkovich</dc:creator><dc:creator>多米尼克·德·纳尔多（Dominic de Nardo）</dc:creator><dc:creator> Sunnie Yoh</dc:creator><dc:creator> Elisha Do Roberson</dc:creator><dc:creator> Sumit K Chanda</dc:creator><dc:creator>大卫·J·卡斯特（David J Kast）</dc:creator><dc:creator>乔纳森·J·米纳（Jonathan J Miner）</dc:creator><dc:date> 2025-02-13</dc:date><dc:source>细胞</dc:source><dc:title>ARFGAP2促进刺激质子通道活性，细胞因子过境和自身炎症</dc:title><dc:identifier>PMID：39947179</dc:identifier><dc:identifier> doi：10.1016/j.cell.2025.01.027</dc:identifier></item><item><title>纤维，脂肪酸和血压：肠道溶液</title><link/>https://pubmed.ncbi.nlm.nih.gov/39946444/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250215151018&amp;v=2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res。2025年2月14日； 136（4）：358-360：10.1161/circresaha.125.326065</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID <a href=https://doi.org/10.1161/CIRCRESAHA.125.326065>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39946444/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250215151018&v=2.18.0.post9+e462414">39946444</a> |</p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39946444</guid><pubDate> Thu, 13 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Mohd Mabood Khan</dc:creator><dc:creator>安妮·基拉博（Annet Kirabo）</dc:creator><dc:date> 2025-02-13</dc:date><dc:source>循环研究</dc:source><dc:title>纤维，脂肪酸和血压：肠道溶液</dc:title><dc:identifier>PMID：39946444</dc:identifier><dc:identifier> doi：10.1161/circresaha.125.326065</dc:identifier></item><item><title>矿物质应力和血管衰老：解码表观遗传连接以减慢时钟</title><link/>https://pubmed.ncbi.nlm.nih.gov/39946443/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250215151018&amp;v=2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> CircRes。20252月14日； 136（4）：400-402：10.1161/circresaha.125.326064</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID <a href=https://doi.org/10.1161/CIRCRESAHA.125.326064>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39946443/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250215151018&v=2.18.0.post9+e462414">39946443</a> |</p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39946443</guid><pubDate> Thu, 13 Feb 2025 06:00:00 -0500</pubDate><dc:creator>列李</dc:creator><dc:creator>lifang ye</dc:creator><dc:creator> Jeffrey J Hsu</dc:creator><dc:date> 2025-02-13</dc:date><dc:source>循环研究</dc:source><dc:title>矿物质应力和血管衰老：解码表观遗传连接以减慢时钟</dc:title><dc:identifier>PMID：39946443</dc:identifier><dc:identifier> doi：10.1161/circresaha.125.326064</dc:identifier></item><item><title>认识第一作者</title><link/>https://pubmed.ncbi.nlm.nih.gov/39946442/？ 708114047＆ff = 20250215151018＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ。2月14日； 136（4）：355-357：10.1161/res.00000000000709</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID <a href=https://doi.org/10.1161/RES.0000000000000709>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39946442/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250215151018&v=2.18.0.post9+e462414">39946442</a> |</p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39946442</guid><pubDate> Thu, 13 Feb 2025 06:00:00 -0500</pubDate><dc:date> 2025-02-13</dc:date><dc:source>循环研究</dc:source><dc:title>认识第一作者</dc:title><dc:identifier>PMID：39946442</dc:identifier><dc:identifier> doi：10.1161/res.00000000709</dc:identifier></item><item><title>解密血小板：它们是细胞还是细胞外囊泡的进化形式？</title><link/> https://pubmed.ncbi.nlm.nih.gov/39946441/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250215151018&amp;v=2.18.0.post9+e462414<description>血小板在血液中含量丰富，它们保持脉管系统的完整性。 ，例如RNA以及从父型巨核细胞传播的细胞器。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res。2025年2月14日； 136（4）：442-452：10.1161/circresaha.124.324721。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">血小板在血液中含量丰富，它们保持脉管系统的完整性。 ，例如RNA以及从父型巨核细胞传播的细胞器。大型细胞碎片是由脂质双层释放的颗粒，这些材料从细胞中释放，但无法像血小板一样复制。可能是细胞，尽管不是常规的细胞，或者可能是先前未识别的细胞外场地。囊泡。</p><p style="color: lightgray"> PMID <a href=https://doi.org/10.1161/CIRCRESAHA.124.324721>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39946441/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250215151018&v=2.18.0.post9+e462414">39946441</a> |</p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39946441</guid><pubDate> Thu, 13 Feb 2025 06:00:00 -0500</pubDate><dc:creator>埃里克·博克（Eric Bootard）</dc:creator><dc:creator>迪伦·汉堡（Dylan Burger）</dc:creator><dc:creator>编辑buzas</dc:creator><dc:creator> Paolo Gresele</dc:creator><dc:creator>凯莉·马赫鲁斯（Kellie R Machlus）</dc:creator><dc:creator>奈杰尔·麦克曼（Nigel Mackman）</dc:creator><dc:creator>皮亚·西尔扬德（Pia Siljander）</dc:creator><dc:creator> Rienk Nieuwland</dc:creator><dc:date> 2025-02-13</dc:date><dc:source>循环研究</dc:source><dc:title>解密血小板：它们是细胞还是细胞外囊泡的进化形式？</dc:title><dc:identifier> PMID：39946441</dc:identifier><dc:identifier> doi：10.1161/circresaha.124.324721</dc:identifier></item><item><title>代谢雄激素类固醇使用者的心血管疾病</title><link/>https://pubmed.ncbi.nlm.nih.gov/39945117/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250215151018&amp;v=2.18.0.post9+e462414<description>结论：AAS的使用与大型队列中的次要增加心血管疾病的风险有关，随访期很长。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>循环</b>。2025年2月13日。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：合成代谢的雄激素类固醇（AASS）与死亡率的增加有关，其中一些死亡是由于心血管疾病的流行病学而导致的测量男性AAS使用者中心血管疾病的事件，并将这些比率与年龄和性别相匹配的总体人群的速率进行比较。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在2006年至2018年之间，在丹麦健身中心使用的AAS使用批准的男性被包括在年龄和性别上，与丹麦一般人群的数量相同，直到2023年6月30日。在全国范围内，我们获得了AAS使用者和控制的信息，有关AAS使用者的入学，处方，教育时间和职业状况。随访期间，中风，心律不齐，心肌衰竭，心力衰竭和心脏骤停。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在11年的随访中，AAS用户（n = 1189）表明，与对照相比，几个心血管事件的事件明显更高（n = 59 450）。心肌梗塞（调整后危险比[AHR] 3.00 [95％CI，1.67-5.39]），经皮冠状动脉介入或冠状动脉搭桥术（AHR 2.95 [95％CI，1.68-5.18]），静脉血栓症（AHR 2.42 [95 [95） ％CI，1.54-3.80]），心律不齐（AHR 2.26 [95％CI，1.53-3.32]），心肌病（AHR 8.90 [95％CI，4.99-15.88]）和心力衰竭（AHR 3.63 [95％CI，CI，CI，CI，CI，CI，95％， 2.01-6.55]）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：AAS的使用与大型队列中的次要增加心血管疾病的风险有关，随访期很长。</p><p style="color: lightgray"> PMID <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071117>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39945117/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250215151018&v=2.18.0.post9+e462414">39945117</a> |</p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39945117</guid><pubDate> Thu, 13 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Josefine Windfeld大理石</dc:creator><dc:creator>Ida M Heerfordt</dc:creator><dc:creator>金·佩德·达霍夫（Kim Peder Dalhoff）</dc:creator><dc:creator>乔恩·特拉鲁普·安徒生</dc:creator><dc:creator>迈克尔·阿斯格·安德森</dc:creator><dc:creator>卡尔·塞巴斯蒂安·约翰逊（Karl Sebastian Johansson）</dc:creator><dc:creator> Tor Biering-Sørensen</dc:creator><dc:creator> Flemming Javier Olsen</dc:creator><dc:creator> Henrik Horwitz</dc:creator><dc:date> 2025-02-13</dc:date><dc:source> Circulation</dc:source><dc:title> Cardiovascular Disease in Anabolic Androgenic Steroid Users</dc:title><dc:identifier> pmid:39945117</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.124.071117</dc:identifier></item><item><title> Evolution of Critical Care Cardiology: An Update on Structure, Care Delivery, Training, and Research Paradigms: A Scientific Statement From the American Heart Association</title><link/> https://pubmed.ncbi.nlm.nih.gov/39945062/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250215151018&amp;v=2.18.0.post9+e462414<description> Critical care cardiology refers to the practice focus of and subspecialty training for the comprehensive management of life-threatening cardiovascular diseases and comorbid conditions that require advanced critical care in an intensive care unit. The development of coronary care units is often credited for a dramatic decline in mortality rates after acute myocardial infarction throughout the 1960s. As the underlying patient population became progressively sicker, changes in organizational... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2025 Feb 13. doi: 10.1161/CIR.0000000000001300. Online ahead of print.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Critical care cardiology refers to the practice focus of and subspecialty training for the comprehensive management of life-threatening cardiovascular diseases and comorbid conditions that require advanced critical care in an intensive care unit. The development of coronary care units is often credited for a dramatic decline in mortality rates after acute myocardial infarction throughout the 1960s. As the underlying patient population became progressively sicker, changes in organizational structure, staffing, care delivery, and training paradigms lagged. The coronary care unit gradually evolved from a focus on rapid resuscitation from ventricular arrhythmias in acute myocardial infarction into a comprehensive cardiac intensive care unit designed to care for the sickest patients with cardiovascular disease. Over the past decade, the cardiac intensive care unit has continued to transform with an aging population, increased clinical acuity, burgeoning cardiac and noncardiac comorbidities, technologic advances in cardiovascular interventions, and increased use of temporary mechanical circulatory support devices. Herein, we provide an update and contemporary expert perspective on the organizational structure, staffing, and care delivery in the cardiac intensive care unit; examine the challenges and opportunities present in the education and training of the next generation of physicians for critical care cardiology; and explore quality improvement initiatives and scientific investigation, including multicenter registry initiatives and randomized clinical trials, that may change clinical practice, care delivery, and the research landscape in this rapidly evolving discipline.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39945062/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250215151018&v=2.18.0.post9+e462414">39945062</a> | DOI: <a href=https://doi.org/10.1161/CIR.0000000000001300>10.1161/CIR.0000000000001300</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39945062</guid><pubDate> Thu, 13 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Shashank S Sinha</dc:creator><dc:creator> Bram J Geller</dc:creator><dc:creator> Jason N Katz</dc:creator><dc:creator> Cynthia Arslanian-Engoren</dc:creator><dc:creator> Christopher F Barnett</dc:creator><dc:creator> Erin A Bohula</dc:creator><dc:creator> Abdulla A Damluji</dc:creator><dc:creator> Venu Menon</dc:creator><dc:creator> Robert O Roswell</dc:creator><dc:creator> Saraschandra Vallabhajosyula</dc:creator><dc:creator> Amanda R Vest</dc:creator><dc:creator> Sean van Diepen</dc:creator><dc:creator> David A Morrow</dc:creator><dc:creator> American Heart Association Acute Cardiac Care and General Cardiology Committee of the Council on Clinical Cardiology; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Cardiovascular and Stroke Nursing; and Council on Kidney in Cardiovascular Disease</dc:creator><dc:date> 2025-02-13</dc:date><dc:source> Circulation</dc:source><dc:title> Evolution of Critical Care Cardiology: An Update on Structure, Care Delivery, Training, and Research Paradigms: A Scientific Statement From the American Heart Association</dc:title><dc:identifier> pmid:39945062</dc:identifier><dc:identifier> doi:10.1161/CIR.0000000000001300</dc:identifier></item><item><title> Novel Directly Reprogrammed Smooth Muscle Cells Promote Vascular Regeneration as Microvascular Mural Cells</title><link/> https://pubmed.ncbi.nlm.nih.gov/39945059/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250215151018&amp;v=2.18.0.post9+e462414<description> CONCLUSIONS: A combination of myocardin and all-trans retinoic acid in defined culture conditions efficiently reprogrammed human fibroblasts into contractile and functional SMCs. The rSMCs were shown to be effective for vascular repair and contributed to neovascularization through mural cells and various paracrine effects. These human rSMCs could represent a novel source for cell-based therapy and research. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2025 Feb 13. doi: 10.1161/CIRCULATIONAHA.124.070217. Online ahead of print.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Although cell therapy has emerged as a promising approach to promote neovascularization, its effects are mostly limited to capillaries. To generate larger or stable vessels, layering of mural cells such as smooth muscle cells (SMCs) or pericytes is required. Recently, direct reprogramming approaches have been developed for generating SMCs. However, such reprogrammed SMCs lack genuine features of contractile SMCs, a native SMC phenotype; thus, their therapeutic and vessel-forming potential in vivo was not explored. Therefore, we aimed to directly reprogram human dermal fibroblasts toward contractile SMCs (rSMCs) and investigated their role for generating vascular mural cells in vivo and their therapeutic effects on ischemic disease. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: We applied myocardin and all- <i>trans</i> retinoic acid with specific culture conditions to directly reprogram human dermal fibroblasts into rSMCs. We characterized their phenotype as contractile SMCs through quantitative reverse-transcriptase polymerase chain reaction, flow cytometry, and immunostaining. We then explored their contractility using a vasoconstrictor, carbachol, and through transmission electron microscope and bulk RNA sequencing. Next, we evaluated whether transplantation of rSMCs improves blood flow and induces vessel formation as mural cells in a mouse model of hind-limb ischemia with laser Doppler perfusion imaging and histological analysis. We also determined their paracrine effects. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Our novel culture conditions using myocardin and all- <i>trans</i> retinoic acid efficiently reprogrammed human dermal fibroblasts into SMCs. These rSMCs displayed characteristics of contractile SMCs at the mRNA, protein, and cellular levels. Transplantation of rSMCs into ischemic mouse hind limbs enhanced blood flow recovery and vascular repair and improved limb salvage. Histological examination showed that vascular density was increased and the engrafted rSMCs were incorporated into the vascular wall as pericytes and vascular SMCs, thereby contributing to formation of stabler and larger microvessels. Quantitative reverse-transcriptase polymerase chain reaction analysis revealed that these transplanted rSMCs exerted pleiotropic effects, including angiogenic, arteriogenic, vessel-stabilizing, and tissue regenerative effects, on ischemic limbs. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: A combination of myocardin and all- <i>trans</i> retinoic acid in defined culture conditions efficiently reprogrammed human fibroblasts into contractile and functional SMCs. The rSMCs were shown to be effective for vascular repair and contributed to neovascularization through mural cells and various paracrine effects. These human rSMCs could represent a novel source for cell-based therapy and research.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39945059/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250215151018&v=2.18.0.post9+e462414">39945059</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070217>10.1161/CIRCULATIONAHA.124.070217</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39945059</guid><pubDate> Thu, 13 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Cholomi Jung</dc:creator><dc:creator> Ji Woong Han</dc:creator><dc:creator> Shin-Jeong Lee</dc:creator><dc:creator> Kyung Hee Kim</dc:creator><dc:creator> Jee Eun Oh</dc:creator><dc:creator> Seongho Bae</dc:creator><dc:creator> Sangho Lee</dc:creator><dc:creator> Young-Jae Nam</dc:creator><dc:creator> Sangsung Kim</dc:creator><dc:creator> Chaewon Dang</dc:creator><dc:creator> Jaehyun Kim</dc:creator><dc:creator> Nakhyung Chu</dc:creator><dc:creator> Eun Jig Lee</dc:creator><dc:creator> Young-Sup Yoon</dc:creator><dc:date> 2025-02-13</dc:date><dc:source> Circulation</dc:source><dc:title> Novel Directly Reprogrammed Smooth Muscle Cells Promote Vascular Regeneration as Microvascular Mural Cells</dc:title><dc:identifier> pmid:39945059</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.124.070217</dc:identifier></item><item><title> Therapeutic left-to-right shunting in heart failure</title><link/> https://pubmed.ncbi.nlm.nih.gov/39943738/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250215151018&amp;v=2.18.0.post9+e462414<description> Heart failure with reduced or preserved ejection fraction are both associated with elevated left atrial pressure at rest due to fluid overload or during exercise, leading to pulmonary venous congestion. Even with available treatments, heart failure hospitalizations remain high, and improvements in quality-of-life scores and functional capacity are modest. Thus, there is growing interest in non-pharmacological methods to decompress the left atrium and improve heart failure symptoms and outcomes.... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 Feb 13:ehaf120. doi: 10.1093/eurheartj/ehaf120. Online ahead of print.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Heart failure with reduced or preserved ejection fraction are both associated with elevated left atrial pressure at rest due to fluid overload or during exercise, leading to pulmonary venous congestion. Even with available treatments, heart failure hospitalizations remain high, and improvements in quality-of-life scores and functional capacity are modest. Thus, there is growing interest in non-pharmacological methods to decompress the left atrium and improve heart failure symptoms and outcomes. Left-to-right shunts have emerged as a potential therapeutic option to reduce left atrial hypertension, improve quality of life, and impact long-term outcomes. This nascent field carries both potential therapeutic promise as well as many unanswered questions. Recent data have questioned whether the effects of this therapy vary based on the left ventricular ejection fraction, pulmonary vascular resistance, and/or right ventricular structure and function. This review discusses the basis for left-to-right shunt therapies, synthesizes past and ongoing clinical trials, and offers future directions.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39943738/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250215151018&v=2.18.0.post9+e462414">39943738</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehaf120>10.1093/eurheartj/ehaf120</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39943738</guid><pubDate> Thu, 13 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Francesco Fioretti</dc:creator><dc:creator> Ajith P Nair</dc:creator><dc:creator> Stefan D Anker</dc:creator><dc:creator> Barry A Borlaug</dc:creator><dc:creator> Dean J Kereiakes</dc:creator><dc:creator> JoAnn Lindenfeld</dc:creator><dc:creator> Gregg W Stone</dc:creator><dc:creator> Javed Butler</dc:creator><dc:date> 2025-02-13</dc:date><dc:source> European heart journal</dc:source><dc:title> Therapeutic left-to-right shunting in heart failure</dc:title><dc:identifier> pmid:39943738</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehaf120</dc:identifier></item><item><title> Clinical implications of perioperative and periprocedural myocardial infarction</title><link/> https://pubmed.ncbi.nlm.nih.gov/39939396/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250215151018&amp;v=2.18.0.post9+e462414<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol. 2025 Feb 12. doi: 10.1038/s41569-025-01137-y. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39939396/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250215151018&v=2.18.0.post9+e462414">39939396</a> | DOI: <a href=https://doi.org/10.1038/s41569-025-01137-y>10.1038/s41569-025-01137-y</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39939396</guid><pubDate> Wed, 12 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Konstantin A Krychtiuk</dc:creator><dc:creator> Christopher B Granger</dc:creator><dc:creator> Bernard J Gersh</dc:creator><dc:date> 2025-02-12</dc:date><dc:source> Nature reviews. Cardiology</dc:source><dc:title> Clinical implications of perioperative and periprocedural myocardial infarction</dc:title><dc:identifier> pmid:39939396</dc:identifier><dc:identifier> doi:10.1038/s41569-025-01137-y</dc:identifier></item></channel></rss>